Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 3INDUSTRY 3OTHER 2

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Breast 2Dermatologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 297Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × glembatumumab vedotin × Clear all
NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT01997333 2019-03-08

METRIC

Celldex Therapeutics

Phase 2 Completed
327 enrolled 17 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01156753 2017-07-02

EMERGE

Celldex Therapeutics

Phase 2 Completed
120 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡